Page last updated: 2024-11-07

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol: NM refers to free form; BMY 14802-1 is the HCl; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108046
CHEMBL ID60859
CHEBI ID91549
SCHEMBL ID467229
MeSH IDM0143955

Synonyms (43)

Synonym
BRD-A15435692-003-01-5
bmy14802
gtpl8
bms-181100
PDSP2_000017
PDSP1_000017
bmy-14802
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol
1-piperazinebutanol, alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-
bmy 14802
L023990
CHEMBL60859 ,
1-(4-fluorophenyl)-4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)butan-1-ol
(r)1-(4-fluoro-phenyl)-4-[4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-butan-1-ol
(s)1-(4-fluoro-phenyl)-4-[4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-butan-1-ol
1-(4-fluoro-phenyl)-4-[4-(4-fluoro-phenyl)-piperazin-1-yl]-butan-1-ol
1-(4-fluoro-phenyl)-1-[4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-butan-1-ol(bmy-14802)
1-(4-fluoro-phenyl)-4-[4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-butan-1-ol(bmy-14802)
bdbm50002238
4-{4-[5-fluoro-2-(4-fluoro-phenyl)-2h-pyrimidin-1-yl]-piperazin-1-yl}-butan-1-ol
1-(4-fluoro-phenyl)-4-[4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-butan-1-ol
4-{4-[5-fluoro-2-(4-fluoro-phenyl)-2h-pyrimidin-1-yl]-piperazin-1-yl}-butan-1-ol(bmy 14802)
1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-ol
105565-56-8
unii-a5nb5g07jo
a5nb5g07jo ,
(+-)-bms 14802
SCHEMBL467229
.alpha.-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol
1-piperazinebutanol, .alpha.-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-
bmy-14802, >=97% (hplc)
CHEBI:91549
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol
(+/-)-bmy-14802
1-piperazinebutanol, a-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-, hydrochloride (1:1);1-piperazinebutanol, a-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-, hydrochloride (1:1)
bmy-14802-1 free
ZXUYYZPJUGQHLQ-UHFFFAOYSA-N
1-(4-fluorophenyl)-4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)-1-butanol
Q4836101
MS-25366
DTXSID70909596
CS-0650370
HY-153091

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The STR was mimicked in mice treated with BD 1047 (a putative σ(1) receptor antagonist), but not SM-21, a putative σ(2) receptor antagonist, in combination with METH."( Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine.
Hall, FS; Kitanaka, J; Kitanaka, N; Nishiyama, N; Takemura, M; Tanaka, K; Uhl, GR, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve was bell-shaped which is typical for cognition enhancers."( PRE-084, a sigma selective PCP derivative, attenuates MK-801-induced impairment of learning in mice.
Maurice, T; Nabeshima, T; Parish, DW; Privat, A; Su, TP, 1994
)
0.29
" In keeping with previous data obtained with other sigma receptor ligands, low doses of sertraline and of clorgyline potentiated selectively with a bell-shaped dose-response curve the effect of N-methyl-D-aspartate (NMDA) on pyramidal neurons in the CA3 region of the rat dorsal hippocampus."( Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
Bergeron, R; De Montigny, C; Debonnel, G, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-arylpiperazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sigma non-opioid intracellular receptor 1Mus musculus (house mouse)Ki0.17400.00190.20180.8200AID204597
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.83000.00011.753610.0000AID5491
Tryptophan 5-hydroxylase 1Rattus norvegicus (Norway rat)IC50 (µMol)6.43000.03801.30806.4300AID64433
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.83000.00040.908610.0000AID5491
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.82670.00021.874210.0000AID36863; AID37003; AID37007
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.91000.00031.38338.4000AID37007; AID4136
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.82670.00021.270410.0000AID36863; AID37003; AID37007
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)1.50000.00051.48357.8000AID37007
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)1.50000.00311.73607.8000AID37007
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)1.50000.00501.79627.8000AID37007
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki0.39100.00000.705610.0000AID204313
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)Ki0.41000.00080.50322.8420AID5025
5-hydroxytryptamine receptor 2AMus musculus (house mouse)Ki0.41000.00080.65892.8420AID5025
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.82670.00001.819410.0000AID36863; AID37003; AID37007
D(2) dopamine receptorMus musculus (house mouse)IC50 (µMol)2.43100.00090.47332.4310AID61051
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)5.73800.00010.54948.4000AID64433; AID64593; AID64613
5-hydroxytryptamine receptor 2BMus musculus (house mouse)Ki0.41000.00080.65892.8420AID5025
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.06000.00030.70285.3660AID204763
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.26500.00000.490110.0000AID204145; AID204153
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.07300.00030.55704.2000AID179240; AID204762; AID204763
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.39100.00030.26715.0700AID204304; AID204313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorCavia porcellus (domestic guinea pig)K0.50.54800.00020.10290.5480AID88625
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.50.18000.00010.40364.8000AID88008
Histamine H3 receptorCavia porcellus (domestic guinea pig)K0.50.54800.00020.10290.5480AID88625
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID36863Inhibition of [3H]WB-4101 binding to rat cortical Alpha-1 adrenergic receptor in vitro1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID204304Ability to displace [3H]ditolylguanidine in the presence of 100 nM (+)-pentazocine from Sigma opioid receptor type 2 of rat liver2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Novel sigma receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] with carbon substituents in position 3.
AID93722Inhibitory concentration against radioligand [3H]-kainic acid binding to kainate receptors in rat cortex1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID37003Inhibitory concentration against radioligand [3H]-WB- 4101 binding to rat cortical Alpha-1 adrenergic receptor1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID4130Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID204597In vitro binding affinity for the mouse sigma opioid receptor1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID131403Oral potency tested by using anti-mescaline test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID40363Inhibition of muscimol binding to GABA-A benzodiazepine receptors in rat cerebellum1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID190627Social interaction time determined in vivo rat at 0.1 mg/kg of ip administration2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Development of a presynaptic 5-HT1A antagonist.
AID204145Ability to displace [3H](+)-pentazocine from Sigma opioid receptor type 1 of guinea pig brain2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Novel sigma receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] with carbon substituents in position 3.
AID176445Oral potency by using Anti aggression test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID204290Ratio of binding affinity towards Sigma opioid receptor type 1 versus Sigma opioid receptor type 22002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Novel sigma receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] with carbon substituents in position 3.
AID178399Effective dose for motor incoordination in rats was determined by rotarod method1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID178397Effective dose for inhibition of spontaneous motor activity in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID229191Inhibition of specific binding of [3H]DTG to sigma receptor in Guinea pig brain membranes1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID221772Inhibition of [3H]muscimol binding to GABA-A of rat cerebellum1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID230925Binding affinities for sigma-1 and sigma 2 receptors, ratio of IC501995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID41606Inhibitory concentration against radioligand [3H]dihydroalprenolol binding to Beta adrenergic receptor in rat cortex1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID415888Displacement of [3H]ditolylguanidine from sigma 2 receptor in rat liver membrane by liquid scintillation analyzer2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
1,4-Diazepanes derived from (S)-serine--homopiperazines with improved sigma(1) (sigma) receptor affinity and selectivity.
AID176444Oral potency tested using 5HTP induced head twitch test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID186977Effect of chronic administration at a peroral dose of 30 mg/Kg qd for 29 days on D2 receptor binding in rat striata1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID176231Effective peroral dose for inhibition of conditioned avoidance response in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID229187Inhibition of specific binding of [125I]PIPAG to sigma receptor in Guinea pig brain membranes1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID88008Displacement of [3H](-)-trans-H2-PAT from Guinea pig histamine H2 receptors.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID178395Effective dose for ethanol potentiation in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID204762Compound was evaluated for the binding affinity towards Sigma receptor type 1 using radioligand ([3H]-(+)- Pentazocine) binding assay.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID204153Sigma opioid receptor type 1 affinity in guinea pig brain by employing [3H](+)-pentazocine as radioligand.2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
AID186976Effect of chronic administration at a peroral dose of 15 mg/Kg qd for 29 days on D2 receptor binding in rat striata1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID233687Selectivity ratio (Sigma1/Sigma2)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
AID64593Inhibitory concentration against radioligand [3H](-)-sulpiride binding to Dopamine receptor D2 in rat1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine sigma ligands as potential antipsychotic drugs.
AID204770Binding affinity towards Sigma receptor site 2 in rat brain using [3H]DTG as radioligand1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID131723Effective dose for inhibition of physostigmine induced lethality in mouse1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID88625Compound was tested for the displacement of [3H]mepyramine from Histamine H1 receptor by competition binding assay1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID144909Inhibitory concentration against radioligand [3H]strychnine binding to glycine site of NMDA receptors in rat medulla pons1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID171006Bmax (D2 receptor number) was determined after peroral administration of 30 mg/Kg in rats qd for 29 days1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID110046Effective dose against (+)-SKF-10047-induced stereotyped behavior in mice was determined1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine sigma ligands as potential antipsychotic drugs.
AID37007Binding affinity towards Alpha-1 adrenergic receptor binding site using [3H]prazosin.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID204763Binding affinity towards sigma receptor binding site 1 using [3H](+)-pentazocine1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID203853Inhibitory concentration against radioligand [3H](+)-NAN binding to haloperidol-sensitive sigma binding site in whole guinea pig brain1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID204772Binding affinity towards sigma receptor binding site 2 using [3H]DTG of whole rat brain homogenates except cerebellum1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID179240Displacement of (+)-[3H]-3-PPP from rat cortical sigma site1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID180317Inhibitory concentration against radioligand [3H]imipramine binding to serotonin uptake site in rat hippocampus1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID415889Selectivity for sigma 1 receptor in guinea pig brain membrane over sigma 2 receptor in rat liver membrane2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
1,4-Diazepanes derived from (S)-serine--homopiperazines with improved sigma(1) (sigma) receptor affinity and selectivity.
AID64613Binding affinity towards Dopamine receptor D2 binding site using [3H]spiroperidol.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID171005Bmax (D2 receptor number) was determined after peroral administration of 15 mg/Kg in rats qd for 29 days1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID131722Effective dose for inhibition of norepinephrine induced lethality in mouse1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID131404Oral potency tested using apomorphine induced climbing test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID204313Sigma opioid receptor type 2 affinity in rat liver by employing [3H]ditolylguanidine as radioligand2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
AID204283Inhibitory concentration against radioligand [3H]3-PPP binding to Sigma opioid receptor type 1 in rat brain membrane1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine sigma ligands as potential antipsychotic drugs.
AID4834Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID64433In vitro inhibitory against radioligand [3H]spiperone binding to rat striatal Dopamine receptor D21992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID61051In vitro binding affinity towards dopamine receptor D21992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID5025In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID36932Inhibitory concentration against radioligand [3H]clonidine binding to Alpha-2 adrenergic receptor in rat cortex1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID184542In vivo motor activity determined in rat at 0.1 mg/kg of ip administration2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Development of a presynaptic 5-HT1A antagonist.
AID61194Inhibitory concentration against radioligand [3H]-SCH- 23390 binding to Dopamine receptor D1 receptors in rat striatum1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID5491Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. 1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID176225Inhibition of apomorphine-induced stereotypy in rats via peroral route1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID176222Effective in vivo peroral dose against induction of catalepsy in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID415887Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane by liquid scintillation analyzer2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
1,4-Diazepanes derived from (S)-serine--homopiperazines with improved sigma(1) (sigma) receptor affinity and selectivity.
AID178400Effective dose for reversal of trifluoperazine-induced catalepsy in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID204764Ratio of the binding affinities against Sigma receptor type 1 and Sigma receptor type 21995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID203854Inhibitory concentration against radioligand [3H]3-PPP binding to haloperidol-sensitive sigma binding site in whole guinea pig brain1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID4136Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. 1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (90)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (8.89)18.7374
1990's69 (76.67)18.2507
2000's11 (12.22)29.6817
2010's2 (2.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.66 (24.57)
Research Supply Index4.52 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.11%)5.53%
Reviews4 (4.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other85 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]